Alzheimer’s doctors see promise, limits in Lilly’s latest drug data

To investors, last week’s news from Eli Lilly was clear-cut.

One of the company’s most closely watched drugs, an experimental treatment for Alzheimer’s disease, had hit every major goal of a large clinical trial evaluating whether it could slow the neurodegenerative disease. Analysts now expect these results to get the drug, named donanemab, approved, handing Lilly what could be another blockbuster product.

But among Alzheimer’s doctors and experts, any kind of consensus around these results has yet to be reached.